Rhythm Pharmaceuticals vs Syndax Pharmaceuticals
Rhythm Pharmaceuticals reported revenue of $190 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Rhythm Pharmaceuticals' revenue grew 45.8% in its latest year, and Syndax Pharmaceuticals' grew 627.8%. Rhythm Pharmaceuticals had an operating margin of -101.2%, against -158.4% at Syndax Pharmaceuticals. Free cash flow was −$117 million at Rhythm Pharmaceuticals and −$323 million at Syndax Pharmaceuticals.
Side by side
| Rhythm Pharmaceuticals | Syndax Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $190M | $172M |
| Revenue growth | 45.8% | 627.8% |
| Revenue growth a year, last 5 years | — | 158.3% |
| Gross margin | 89.7% | — |
| Operating margin | −101.2% | −158.4% |
| Net margin | −103.6% | −165.6% |
| Free cash flow | −$117M | −$323M |
| Free cash flow margin | −61.5% | −187.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.5% | 1.2% |
| Last close | $115.02 | $9.45 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $36.4 million | sold $2.7 million |
| Piotroski F-score | 6 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Rhythm PharmaceuticalsSyndax Pharmaceuticals
Operating margin
Percent of revenue
Rhythm PharmaceuticalsSyndax Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rhythm PharmaceuticalsSyndax Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rhythm Pharmaceuticals and Syndax Pharmaceuticals pages.